MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, LONA had $20,838K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$20,838K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from pipe financing
    • Non-cash consideration for acqui...
    • Maturities of available-for-sale...
    • Others
Negative Cash Flow Breakdown
    • Purchases of available-for-sale ...
    • Accounts payable and accrued lia...
    • Issuance costs from pipe financi...
    • Others

Cash Flow
2025-12-31
Net loss
-105,609
Non-cash consideration for acquired in-process research and development
67,659
Change in fair value of sermonix pre-funded warrant
4,579
Stock-based compensation
6,102
Depreciation expense
972
Non-cash lease expense
273
Amortization of premiums and accretion of discounts on available-for-sale securities, net
329
Prepaid expenses and other current and long-term assets, net
-2,439
Accounts payable and accrued liabilities
-21,342
Operating lease liability
-414
Other long-term liabilities
-59
Net cash used in operating activities
-45,729
Purchases of available-for-sale securities
37,643
Maturities of available-for-sale securities
21,749
Net cash (used in) provided by investing activities
-15,894
Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan
37
Proceeds from pipe financing
89,991
Issuance costs from pipe financing
7,567
Net cash provided by financing activities
82,461
Net increase (decrease) in cash, cash equivalents and restricted cash
20,838
Cash, cash equivalents and restricted cash, beginning of period
49,069
Cash, cash equivalents and restricted cash, end of period
69,907
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from pipefinancing$89,991K Proceeds from exercise ofcommon stock options...$37K Net cash provided byfinancing activities$82,461K Canceled cashflow$7,567K Net increase(decrease) in cash, cash...$20,838K Canceled cashflow$61,623K Issuance costs from pipefinancing$7,567K Non-cash considerationfor acquired...$67,659K Stock-based compensation$6,102K Change in fair value ofsermonix pre-funded...$4,579K Prepaid expenses andother current and...-$2,439K Depreciation expense$972K Non-cash lease expense$273K Maturities ofavailable-for-sale securities$21,749K Net cash used inoperating activities-$45,729K Net cash (used in)provided by investing...-$15,894K Canceled cashflow$82,024K Canceled cashflow$21,749K Net loss-$105,609K Purchases ofavailable-for-sale securities$37,643K Accounts payable andaccrued liabilities-$21,342K Operating lease liability-$414K Amortization of premiums andaccretion of discounts on...$329K Other long-termliabilities-$59K

LeonaBio, Inc. (LONA)

LeonaBio, Inc. (LONA)